The European Myeloma Platform said it welcomed new research which found that previously treated multiple myeloma patients who received Revlimid with dexamethasone had an unprecedented nearly three year median survival rate – the longest median survival ever observed in Phase III trials of this patient group.
The research published in this week’s New England Journal of Medicine showed that in addition to increased overall survival, the findings from the two large, US and international clinical trials found that patients who received the oral cancer therapy in combination with the steroid dexamethasone also had increased response rates, time-to-disease progression and duration of response compared to patients treated with the steroid alone.
“The EMP is excited by the potential impact that novel therapies, such as Revlimid are having on the treatment of multiple myeloma patients,” said EMP Chairperson Dr Rolf Pelzing.
“From personal experience, I can testify to the positive benefits of Revlimid for patients. The EMP hopes that ongoing research, like these major international trials, will help to further the understanding of multiple myeloma and enable health care providers to have the necessary tools to turn the disease into a chronic, manageable condition.”
Revlimid (lenalidomide) from Celgene is the newest novel therapy to have changed the outlook for myeloma patients and are helping patients live longer with a better quality of life.
It has been approved in combination with dexamethasone for patients who have received at least one prior therapy in the US and Europe.